To buy or not to buy Abbott Labs? In this video, Fool health care analyst Brenton Flynn gives three reasons why you should. First, health care spending is likely to grow both in the U.S. and in emerging markets. Second, Abbott's nutrition division offers not only baby formula that is increasingly popular in emerging markets, but also diet supplements for older adults, a growing market domestically. Lastly, Abbott should increase its earnings by streamlining its operations and improving business efficiency.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
